- Home
- IVD
- By Technology Types
- By Diseases Types
- By Product Types
- Research
- Resource
- Distributors
- Company
| Product Name | mRNA Transfection Reagent, Low Cytotoxicity for Sensitive Cells |
| Catalog No. | ATR-CTR-0008 |
| Description | A specialized lipid-based delivery reagent optimized for the transfection of in vitro transcribed mRNA into mammalian cells, enabling transient protein expression without the risk of genomic integration. |
| Intended Use | Delivery of in vitro transcribed mRNA for transient protein expression in vaccine research, cell reprogramming experiments, CRISPR base editor expression, and applications requiring integration-free gene delivery. |
| Principle / Technology | mRNA-lipid complexes deliver mRNA directly to the cytoplasm where it is immediately translated by ribosomes; bypassing the nuclear entry step eliminates the requirement for cell division and avoids the risk of insertional mutagenesis inherent in DNA-based systems. |
| Detection Method | Protein expression by reporter flow cytometry or ELISA, cell viability by MTT or flow cytometry, expression kinetics by time-course fluorescent imaging |
| Sample Type | Primary cells, stem cells, immune cells, and cell lines where DNA transfection is inefficient or DNA-free expression is required |
| Performance Range / Specifications | >90% of cells express reporter protein at 6–24 hours post-transfection; cell viability >85% at optimal mRNA dose |
| Sensitivity / LOD | N/A |
| Specificity | N/A |
| Reaction Conditions / Protocol | Dilute mRNA and reagent separately in buffer; mix and incubate 5 min; add to cells; protein expression detectable within 1–2 hours; expression duration 24–72 hours depending on mRNA stability. |
| Components / Formulation | Proprietary lipid blend, mRNA-complexing buffer |
| Storage Conditions | 2–8°C; buffer at 15–30°C |
| Shelf Life | 12 months; buffer 24 months |
| Package Specifications | 0.75 mL reagent + 25 mL buffer, for ~250 reactions (24-well) |
| Product Form | Liquid reagent with buffer |
| Quality Control | EGFP mRNA transfection efficiency in human fibroblasts, viability assessment, RNase-free certification |
| Key Features | Integration free; rapid expression; low cytotoxicity; suitable for sensitive cells; RNase free; validated for cell reprogramming and vaccine research |
For research use only, not for clinical use.
|
There is no product in your cart. |
Copyright © 2026 Alta DiagnoTech. All rights reserved.
